

Key Issues Report		
Report Date: 30 January 2023		Report of: Finance and Performance Assurance Committee
Date of meeting: 24 January 2023		NED members David Brown and Teresa Boughey, together with new Chair Rajinder Dhaliwal, were present. Helen Troalen (Director of Finance) was also present. Attending were Sara Biffen (Acting Chief Operating Officer) and Nigel Lee (Interim Director of Strategy and Partnerships) The meeting was quorate.
1	Agenda	The Committee considered the following: <ul style="list-style-type: none"> • Finance Report, Month 9 • Update on cash position • Draft Integrated Performance Report, Month 9 • 2023/2024 Planning • Strategy and Partnership Update • Quarterly People and OD Report • Security Contract Tender • Board Assurance Framework, Q3 • Update reports from:- <ul style="list-style-type: none"> • Capital Planning Group • Efficiency and Sustainability Group
2a	Alert <i>Matters of concerns, gaps in assurance or key risks to escalate to the Board</i>	<ul style="list-style-type: none"> • Following discussions with NHS England regarding the forecast outturn for the financial year, £47.5m deficit had been put forward. • The Trust's draft 2023/24 plan shows £62.8m deficit, and it is anticipated that this will not be acceptable to NHSE – this needs more work and prioritisation. • There is potentially a risk that the Trust will not be able to fully deliver all of the 2023/24 national operating plan metrics. • In December 2022, the 78-week waiting list had been forecasted to comprise 211 patients. Having now further reviewed the waiting list, the absolute minimum number of patients affected would be 446, across all specialities – and there would be variation between specialities. • The committee noted that there were 665 patients waiting over 62 days for diagnosis, or treatment, on cancer pathways. • The Committee was advised that NHSE would provide capital to purchase an ambulance receiving area at the Princess Royal Hospital. However, the regulator had stipulated that this must be operational by 1 April 2023.
2b	Assurance <i>Positive assurances and highlights of note for the Board</i>	<ul style="list-style-type: none"> • The capital programme remains on track, although the Committee noted that any potential slippage will be offset by pulling forward elements from the 2023/24 Q1 plan. • The Clinical Services Strategy is being finalised. • The Finance Governance Group is in place to ensure that there is a weekly executive forum with oversight of the daily expenditure and rates, to year end.

2c	Advise <i>Areas that continue to be reported on and/or where some assurance has been noted</i>	<ul style="list-style-type: none"> The Trust has received approval from the national team for the full amount of CDC capital. 		
2d	Actions <i>Significant follow up actions</i>	<ul style="list-style-type: none"> None 		
3	Report compiled by	<i>Anna Milanec, in conjunction with Rajinder Dhaliwal, Committee Chair</i>	Minutes available from	<i>Julie Harris,</i>